Radioligand therapy for HER2-positive cancers enters human trials for the first time (opens in new tab)

Covers 2 stories including Andrew Zinin - Science X

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.

Read the original article